Loading
Latest filing published 23 Feb 2022 for Evofem Biosciences, Inc..
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Justin J. File on record concern Evofem Biosciences, Inc., in the capacity of finance chief. The record holds 26 filings, for trades running from 2 July 2018 to 18 February 2022.
In open-market terms, that means 4 purchases worth €72k on one side and 5 sales worth €119k on the other. Sales outweigh purchases by €47k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 16 share grants.
Half of the purchases are above €17k and half below.
On 23 February 2022 came the latest disclosure, a share grant in Evofem Biosciences, Inc. The last purchase on record was published on 20 December 2021, which is 1,770 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 26 declarations